PubRank

Remo Guerrini

Author PubWeight™ 95.86‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature 2012 2.96
2 Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain. Eur J Biochem 2002 1.99
3 The alpha-to-beta conformational transition of Alzheimer's Abeta-(1-42) peptide in aqueous media is reversible: a step by step conformational analysis suggests the location of beta conformation seeding. Chembiochem 2006 1.70
4 Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties. J Med Chem 2002 1.40
5 Potent delta-opioid receptor agonists containing the Dmt-Tic pharmacophore. J Med Chem 2002 1.23
6 [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br J Pharmacol 2002 1.14
7 Structure-activity studies on neuropeptide S: identification of the amino acid residues crucial for receptor activation. J Biol Chem 2006 1.13
8 Anxiolytic-like effect of neuropeptide S in the rat defensive burying. Peptides 2008 1.08
9 Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. J Neurosci 2005 1.06
10 Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist. Peptides 2007 1.05
11 Long-lasting antinociceptive spinal effects in primates of the novel nociceptin/orphanin FQ receptor agonist UFP-112. Pain 2009 1.05
12 In vitro and in vivo pharmacological characterization of the neuropeptide s receptor antagonist [D-Cys(tBu)5]neuropeptide S. J Pharmacol Exp Ther 2008 1.05
13 Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. Eur J Pharmacol 2004 1.04
14 Solution structure of amyloid beta-peptide (25-35) in different media. J Med Chem 2004 1.04
15 UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor. CNS Drug Rev 2005 1.01
16 Solution structure of ZASP PDZ domain; implications for sarcomere ultrastructure and enigma family redundancy. Structure 2004 0.99
17 Further studies on the pharmacological profile of the neuropeptide S receptor antagonist SHA 68. Peptides 2010 0.97
18 Direct influence of C-terminally substituted amino acids in the Dmt-Tic pharmacophore on delta-opioid receptor selectivity and antagonism. J Med Chem 2004 0.96
19 Synthesis and biological activity of human neuropeptide S analogues modified in position 2. J Med Chem 2008 0.95
20 A new ligand for the urotensin II receptor. Br J Pharmacol 2002 0.95
21 Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein G alpha qi5. Naunyn Schmiedebergs Arch Pharmacol 2009 0.95
22 Interaction of calmodulin with the phosphofructokinase target sequence. FEBS Lett 2004 0.95
23 Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior. J Neurosci 2004 0.95
24 Conformation-activity relationship of neuropeptide S and some structural mutants: helicity affects their interaction with the receptor. J Med Chem 2007 0.94
25 In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor. Peptides 2007 0.93
26 Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24. Eur J Pharmacol 2009 0.92
27 Central injections of nocistatin or its C-terminal hexapeptide exert anxiogenic-like effect on behaviour of mice in the plus-maze test. Br J Pharmacol 2002 0.91
28 Immunosensing by a Synthetic Ligand-Gated Ion Channel Financial support from the board of the Swiss Federal Institutes of Technology (SPP Minast, 7.06) is acknowledged. We thank G. Corradin for numerous discussions and J. Lakey for critical reading of the manuscript. Angew Chem Int Ed Engl 2001 0.91
29 Conversion of the potent delta-opioid agonist H-Dmt-Tic-NH-CH(2)-bid into delta-opioid antagonists by N(1)-benzimidazole alkylation(1). J Med Chem 2005 0.91
30 Pharmacological characterization of the nociceptin receptor which mediates reduction of alcohol drinking in rats. Peptides 2002 0.90
31 Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase. Proc Natl Acad Sci U S A 2011 0.90
32 In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4-11) (UFP-803). Br J Pharmacol 2006 0.89
33 The nociceptin/orphanin FQ-NOP receptor antagonist effects on an animal model of sepsis. Intensive Care Med 2008 0.89
34 Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release. J Neurochem 2004 0.89
35 Pharmacological profile of nociceptin/orphanin FQ receptors. Clin Exp Pharmacol Physiol 2002 0.89
36 Synthesis and opioid activity of N,N-dimethyl-Dmt-Tic-NH-CH(R)-R' analogues: acquisition of potent delta antagonism. Bioorg Med Chem 2003 0.89
37 [Arg(14),Lys(15)]nociceptin, a highly potent agonist of the nociceptin/orphanin FQ receptor: in vitro and in vivo studies. J Pharmacol Exp Ther 2002 0.89
38 Chronic treatment with the selective NOP receptor antagonist [Nphe 1, Arg 14, Lys 15]N/OFQ-NH 2 (UFP-101) reverses the behavioural and biochemical effects of unpredictable chronic mild stress in rats. Psychopharmacology (Berl) 2009 0.88
39 Structure-activity study at positions 3 and 4 of human neuropeptide S. Bioorg Med Chem 2008 0.88
40 Hypothalamic neuropeptide S receptor blockade decreases discriminative cue-induced reinstatement of cocaine seeking in the rat. Psychopharmacology (Berl) 2012 0.88
41 Copper binding to the neurotoxic peptide PrP106-126: thermodynamic and structural studies. Chembiochem 2004 0.86
42 Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist. Bioorg Med Chem 2005 0.86
43 Ligands raise the constraint that limits constitutive activation in G protein-coupled opioid receptors. J Biol Chem 2013 0.86
44 Pharmacological characterization of tachykinin tetrabranched derivatives. Br J Pharmacol 2014 0.86
45 Synthesis and separation of the enantiomers of the neuropeptide S receptor antagonist (9R/S)-3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68). J Med Chem 2011 0.86
46 Neuropeptide S: a novel regulator of pain-related amygdala plasticity and behaviors. J Neurophysiol 2013 0.86
47 Proinflammatory and vasodilator effects of nociceptin/orphanin FQ in the rat mesenteric microcirculation are mediated by histamine. Am J Physiol Heart Circ Physiol 2007 0.85
48 Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide. Bioorg Med Chem 2009 0.85
49 Blockade of adenosine A2A receptor counteracts neuropeptide-S-induced hyperlocomotion in mice. Naunyn Schmiedebergs Arch Pharmacol 2009 0.84
50 Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: pharmacological and genetic evidences. Pain 2006 0.84
51 Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with Calpha,alpha-dialkylated amino acids. Bioorg Med Chem 2007 0.84
52 [(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor. J Pharmacol Exp Ther 2004 0.83
53 Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias. J Neurosci 2012 0.83
54 The paraventricular nucleus of the hypothalamus is a neuroanatomical substrate for the inhibition of palatable food intake by neuropeptide S. Eur J Neurosci 2009 0.83
55 The SH3 domain of nebulin binds selectively to type II peptides: theoretical prediction and experimental validation. J Mol Biol 2002 0.83
56 Functional selectivity of nociceptin/orphanin FQ peptide receptor partial agonists on cardiovascular and renal function. J Pharmacol Exp Ther 2005 0.83
57 Binding of the novel radioligand [(3)H]UFP-101 to recombinant human and native rat nociceptin/orphanin FQ receptors. Naunyn Schmiedebergs Arch Pharmacol 2008 0.82
58 The interaction of highly helical structural mutants with the NOP receptor discloses the role of the address domain of nociceptin/orphanin FQ. Chemistry 2005 0.82
59 Nociceptin/orphanin FQ receptor activation decreases the airway hyperresponsiveness induced by allergen in sensitized mice. Am J Physiol Lung Cell Mol Physiol 2013 0.82
60 Anxiolytic- and panicolytic-like effects of Neuropeptide S in the mouse elevated T-maze. Eur J Neurosci 2012 0.82
61 Urotensin II stimulates plasma extravasation in mice via UT receptor activation. Naunyn Schmiedebergs Arch Pharmacol 2004 0.82
62 UFP-101 antagonizes the spinal antinociceptive effects of nociceptin/orphanin FQ: behavioral and electrophysiological studies in mice. Peptides 2006 0.82
63 CuII binding sites located at His-96 and His-111 of the human prion protein: thermodynamic and spectroscopic studies on model peptides. Dalton Trans 2008 0.81
64 Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex. Br J Pharmacol 2003 0.81
65 Activation of the nociceptin/orphanin FQ receptor reduces bronchoconstriction and microvascular leakage in a rabbit model of gastroesophageal reflux. Br J Pharmacol 2005 0.81
66 Effect of neuropeptide S receptor antagonists and partial agonists on palatable food consumption in the rat. Peptides 2010 0.81
67 UFP-112 a potent and long-lasting agonist selective for the Nociceptin/Orphanin FQ receptor. CNS Neurosci Ther 2010 0.81
68 Unexpected impact of the number of glutamine residues on metal complex stability. Metallomics 2013 0.81
69 Effects of nociceptin/orphanin FQ receptor ligands on blood pressure, heart rate, and plasma catecholamine concentrations in guinea pigs. Naunyn Schmiedebergs Arch Pharmacol 2003 0.81
70 Modeling of overloaded gradient elution of nociceptin/orphanin FQ in reversed-phase liquid chromatography. J Chromatogr A 2005 0.81
71 Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity. Naunyn Schmiedebergs Arch Pharmacol 2006 0.80
72 Gastrointestinal effects of intracerebroventricularly injected nociceptin/orphaninFQ in rats. Peptides 2004 0.80
73 Urodynamic effects of intravesical nociceptin/orphanin FQ in neurogenic detrusor overactivity: a randomized, placebo-controlled, double-blind study. Urology 2003 0.80
74 New approaches to high-throughput structure characterization of SH3 complexes: the example of Myosin-3 and Myosin-5 SH3 domains from S. cerevisiae. Protein Sci 2006 0.80
75 Peripheral mechanisms involved in gastric mucosal protection by intracerebroventricular and intraperitoneal nociceptin in rats. Endocrinology 2005 0.80
76 Mixed tridentate π -donor and monodentate π -acceptor ligands as chelating systems for rhenium-188 and technetium-99m nitrido radiopharmaceuticals. Curr Radiopharm 2013 0.79
77 Synthesis and antimicrobial activity of dermaseptin S1 analogues. Bioorg Med Chem 2008 0.79
78 Nociceptin modulates bronchoconstriction induced by sensory nerve activation in mouse lung. Am J Respir Cell Mol Biol 2009 0.79
79 Role of the ecto-nucleotidases in the cooperative effect of adenosine and neuropeptide-S on locomotor activity in mice. Pharmacol Biochem Behav 2011 0.79
80 Effects of [(pF)Phe(4)]nociceptin/orphanin FQ-(1-13)NH(2) on GTPgamma(35)S binding and cAMP formation in Chinese hamster ovary cells expressing the human nociceptin/orphanin FQ receptor. Eur J Pharmacol 2002 0.79
81 Nociceptin/orphanin FQ modulates motor behavior and primary motor cortex output through receptors located in substantia nigra reticulata. Neuropsychopharmacology 2008 0.79
82 Intrathecal [Nphe1]nociceptin( 1-13)NH2 selectively reduces the spinal inhibitory effect of nociceptin. Life Sci 2002 0.78
83 Neuropeptide S inhibits stress-stimulated faecal output in the rat. Pharmacol Res 2011 0.78
84 Crystal structures of dipeptides containing the Dmt-Tic pharmacophore. J Med Chem 2002 0.78
85 Pharmacological characterisation of [(pX)Phe4]nociceptin(1-13)amide analogues. 1. In vitro studies. Naunyn Schmiedebergs Arch Pharmacol 2002 0.78
86 Urotensin II evokes neurotransmitter release from rat cerebrocortical slices. Neurosci Lett 2008 0.78
87 Further studies on the pharmacological features of the nociceptin/orphanin FQ receptor ligand ZP120. Peptides 2008 0.78
88 Structural and dynamic characterization of copper(II) binding of the human prion protein outside the octarepeat region. Chemistry 2007 0.78
89 Internalization and stability of a thymidylate synthase Peptide inhibitor in ovarian cancer cells. J Med Chem 2014 0.78
90 Study of synthetic peptides derived from the PKI55 protein, a protein kinase C modulator, in human neutrophils stimulated by the methyl ester derivative of the hydrophobic N-formyl tripeptide for-Met-Leu-Phe-OH. FEBS J 2007 0.77
91 Copper-ion interaction with the 106-113 domain of the prion protein: a solution-equilibria study on model peptides. Dalton Trans 2005 0.77
92 The nociceptin/orphanin FQ receptor antagonist UFP-101 reduces microvascular inflammation to lipopolysaccharide in vivo. PLoS One 2013 0.77
93 Effects of chronic nociceptin/orphanin FQ exposure on cAMP accumulation and receptor density in Chinese hamster ovary cells expressing human nociceptin/orphanin FQ receptors. Eur J Pharmacol 2002 0.77
94 Nociceptin/orphanin FQ prevents ethanol-induced gastric lesions in the rat. Regul Pept 2005 0.77
95 The coordination of NiII and Cu(II) ions to the polyhistidyl motif of Hpn protein: is it as strong as we think? Chemistry 2012 0.77
96 Nociceptin/orphanin FQ inhibits electrically induced contractions of the human bronchus via NOP receptor activation. Peptides 2005 0.77
97 Optimization of peptides that target human thymidylate synthase to inhibit ovarian cancer cell growth. J Med Chem 2014 0.77
98 Mass spectrometric/bioinformatic identification of a protein subset that characterizes the cellular activity of anticancer peptides. J Proteome Res 2014 0.77
99 Daily intravesical instillation of 1 mg nociceptin/orphanin FQ for the control of neurogenic detrusor overactivity: a multicenter, placebo controlled, randomized exploratory study. J Urol 2006 0.77
100 In vitro and in vivo pharmacological characterization of the nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-ol. Eur J Pharmacol 2006 0.76
101 Desensitisation of native and recombinant human urotensin-II receptors. Naunyn Schmiedebergs Arch Pharmacol 2009 0.76
102 [Nphe(1)]N/OFQ-(1-13)-NH(2) is a competitive and selective antagonist at nociceptin/orphanin FQ receptors mediating K(+) channel activation in rat periaqueductal gray slices. Neuropharmacology 2002 0.76
103 Proteinase-activated receptor-1 (PAR-1) activation contracts the isolated human renal artery in vitro. Br J Pharmacol 2003 0.76
104 Role of nociceptin/orphanin FQ receptors in the decrease of mucosal mast cells caused by acute stress in the rat colon. Life Sci 2011 0.76
105 Pharmacological characterisation of [(pX)Phe4]nociceptin(1-13)NH2 analogues. 2. In vivo studies. Naunyn Schmiedebergs Arch Pharmacol 2002 0.76
106 GABA(A) signalling is involved in N/OFQ anxiolytic-like effects but not in nocistatin anxiogenic-like action as evaluated in the mouse elevated plus maze. Peptides 2008 0.76
107 Functional coupling of the nociceptin/orphanin FQ receptor in dog brain membranes. Brain Res 2004 0.75
108 Quantitative study of [(pF)Phe4,Arg14,Lys15]nociceptin/orphanin FQ-NH2 (UFP-102) at NOP receptors in rat periaqueductal gray slices. Eur J Pharmacol 2007 0.75
109 Chronic intracerebroventricular infusion of nociceptin/orphanin FQ increases food and ethanol intake in alcohol-preferring rats. Peptides 2006 0.75
110 The unusual metal ion binding ability of histidyl tags and their mutated derivatives. Dalton Trans 2016 0.75
111 The hypothalamus-pituitary-adrenal axis does not influence the protective effects of nociceptin/orphanin FQ on the rat gastric mucosa. Regul Pept 2008 0.75
112 In vitro activity of dermaseptin S1 derivatives against genital pathogens. APMIS 2010 0.75
113 Thermodynamic and spectroscopic investigation on the role of Met residues in Cu(II) binding to the non-octarepeat site of the human prion protein. Metallomics 2012 0.75
114 Correction to "Mass Spectrometric/Bioinformatic Identification of a Protein Subset That Characterizes the Cellular Activity of Anticancer Peptides". J Proteome Res 2016 0.75
115 Structure-activity relationship study of position 4 in the urotensin-II receptor ligand U-II(4-11). Peptides 2007 0.75
116 Effects of neuropeptide S on seizures and oxidative damage induced by pentylenetetrazole in mice. Pharmacol Biochem Behav 2012 0.75
117 Characterization of nociceptin/orphanin FQ binding sites in dog brain membranes. Anesth Analg 2003 0.75
118 [Nphe1,Arg14,Lys15]N/OFQ-NH2 is a competitive antagonist of NOP receptors in the periaqueductal gray. Eur J Pharmacol 2005 0.75
119 Solution structure of nociceptin peptides. J Pept Sci 2002 0.75
120 Nociceptin/orphanin FQ induces simultaneously anxiolytic and amnesic effects in the mouse elevated T-maze task. Naunyn Schmiedebergs Arch Pharmacol 2014 0.75
121 N-carbamidoyl-4-((3-ethyl-2,4,4-trimethylcyclohexyl)methyl)benzamide enhances staurosporine cytotoxic effects likely inhibiting the protective action of Magmas toward cell apoptosis. J Med Chem 2014 0.75
122 Nociceptin/orphanin FQ prevents gastric damage induced by cold-restraint stress in the rat by acting in the periphery. Peptides 2007 0.75
123 Anti-inflammatory and analgesic effects displayed by peptides derived from PKI55 protein, an endogenous protein kinase C inhibitor. Naunyn Schmiedebergs Arch Pharmacol 2010 0.75
124 Structure-activity relationship study on Tyr9 of urotensin-II(4-11): identification of a partial agonist of the UT receptor. Peptides 2009 0.75